Next quarter’s earnings estimate for ANTX is -$0.24 with a range of -$0.24 to -$0.24. The previous quarter’s EPS was -$0.31. ANTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ANTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for ANTX is -$0.24 with a range of -$0.24 to -$0.24. The previous quarter’s EPS was -$0.31. ANTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ANTX has Performed in-line its overall industry.
No data currently available
ANTX Sales Forecast
Next quarter’s sales forecast for ANTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ANTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ANTX has Performed in-line its overall industry.
Next quarter’s sales forecast for ANTX is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ANTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ANTX has Performed in-line its overall industry.
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (NASDAQ: MMSI), CVS Health (NYSE: CVS) and AN2 Therapeutics, Inc. (NASDAQ: ANTX)
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (NASDAQ: MMSI), CVS Health (NYSE: CVS) and AN2 Therapeutics, Inc. (NASDAQ: ANTX)
trades and holding each position for 1 Month would result in 45.45% of your transactions generating a profit, with an average return of -8.06% per trade.
trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of -17.77% per trade.
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -22.43% per trade.
trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of -24.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ANTX Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jul 25
Aug 25
Strong Buy
5
4
2
1
1
Buy
0
0
0
0
0
Hold
5
5
5
3
3
Sell
3
6
5
5
2
Strong Sell
0
0
0
0
0
total
13
15
12
9
6
In the current month, ANTX has received 1Buy Ratings, 3Hold Ratings, and 2Sell Ratings. ANTX average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.
ANTX Stock Forecast FAQ
What is ANTX’s average 12-month price target, according to analysts?
Currently, no data Available
What is ANTX’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for ANTX, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ANTX a Buy, Sell or Hold?
AN2 Therapeutics, Inc. has a consensus rating of Hold which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
What is AN2 Therapeutics, Inc.’s price target?
Currently, no data Available
What do analysts say about AN2 Therapeutics, Inc.?
AN2 Therapeutics, Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 0 Wall Streets Analysts.
How can I buy shares of ANTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.